Poor Response to Bevacizumab Correlates With Higher IL-6 and IL-8 Aqueous Cytokines in AMD
Investigative Ophthalmology & Visual Science · 2024-09-26 · 65 (11) · 37
DOI: 10.1167/iovs.65.11.37 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, published on 2024-09-26. Written by Emma Connolly and 4 co-authors. Institution: Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland. Major MEDLINE topics: Bevacizumab, Angiogenesis Inhibitors, Intravitreal Injections, Tomography, Optical Coherence. Cited 9 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Purpose
To evaluate the effect of intravitreal bevacizumab on aqueous levels of a panel of 12 inflammatory cytokines in patients with neovascular age-related macular degeneration (nAMD) and correlate response to treatment, as measured by change in the central subfovea thickness (CST), with cytokine levels.
Methods
Thirty-three treatment-naïve patients with nAMD received a loading dose of intravitreal bevacizumab consisting of three injections at six weekly intervals. The aqueous samples prior to the first (baseline), second (week 6), and third (week 12) injections were analyzed for cytokine levels. Participants were subgrouped based on changes in CST on spectral-domain optical coherence tomography (SD-OCT) at 12 weeks. Group 1 included patients with a decrease in CST (responders; n = 27). Group 2 included patients who had no decrease in CST (poor responders; n = 6).
Results
Aqueous IL-8 was the only cytokine to demonstrate a significant difference in levels between responders and poor responders, with higher interleukin-8 (IL-8) at week 12 in the poor responder group. Aqueous IL-6 and IL-8 levels showed a positive correlation with CST on SD-OCT (Spearman r = 0.45 and 0.55, respectively). There was a temporal increase overall in cytokine concentration accompanying bevacizumab treatment.
Conclusions
Aqueous IL-6 and IL-8 may be important markers of treatment response or poor response in nAMD. Future therapeutic strategies may include targeted treatment against both vascular endothelial cell growth factor (VEGF) and IL-6 and/or IL-8 in patients who do not respond to anti-VEGF treatment alone.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, Ireland.
- Trinity College Institute of Neuroscience, Trinity College Dublin, Ireland.
- Research Foundation, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
- Progressive Vision Research, Sandyford, Dublin, Ireland.
Cite
APA
Connolly, E., El-Farouki, G., Brennan, K., Cahill, M., & Doyle, S. L. (2024). Poor Response to Bevacizumab Correlates With Higher IL-6 and IL-8 Aqueous Cytokines in AMD. Investigative Ophthalmology & Visual Science, 65(11), 37. https://doi.org/10.1167/iovs.65.11.37
Vancouver
Connolly E, El-Farouki G, Brennan K, Cahill M, Doyle SL. Poor Response to Bevacizumab Correlates With Higher IL-6 and IL-8 Aqueous Cytokines in AMD. Investigative Ophthalmology & Visual Science. 2024;65(11):37. doi:10.1167/iovs.65.11.37
BibTeX
@article{Connolly2024,
author = {Connolly, Emma and El-Farouki, Ghaleb and Brennan, Kiva and Cahill, Mark and Doyle, Sarah L},
title = {Poor Response to Bevacizumab Correlates With Higher IL-6 and IL-8 Aqueous Cytokines in AMD},
journal = {Investigative Ophthalmology & Visual Science},
year = {2024},
volume = {65},
number = {11},
pages = {37},
doi = {10.1167/iovs.65.11.37}
}
EUVIMED